Anavex Life Sciences AVXL

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.11 (+1.28%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Anavex Life Sciences (AVXL)
    Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $8.67

    • Market Cap

      $737.51 Million

    • Price-Earnings Ratio

      -15.76

    • Total Outstanding Shares

      85.06 Million Shares

    • Total Employees

      2

    • Dividend

      No dividend

    • IPO Date

      August 2, 2006

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      630 5th avenue, New york, NY, 10111

    • Homepage

      https://www.anavex.com

    Historical Stock Splits

    If you bought 4 shares of AVXL before October 7, 2015, you'd have 1 share today.
    Execution DateSplit Amount
    October 7, 20151-for-4 (Reverse Split)

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow From Investing Activities$22.99 Million
    Net Cash Flow From Operating Activities, Continuing$-35.61 Million
    Net Cash Flow$0
    Net Cash Flow From Financing Activities$12.62 Million
    Net Cash Flow, Continuing$0
    Net Cash Flow From Investing Activities, Continuing$22.99 Million

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Basic Average Shares$252.25 Million
    Interest Income/Expense Operating, Net$6.71 Million
    Other Operating Expenses$11.58 Million
    Revenues$6.71 Million
    Nonoperating Income/Loss$8.60 Million
    Net Income/Loss Attributable To Noncontrolling Interest$0

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-46.49 Million
    Other Comprehensive Income/Loss$0
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-46.49 Million

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Liabilities And Equity$124.04 Million
    Liabilities$13.13 Million
    Assets$124.04 Million
    Noncurrent Assets$0
    Equity$110.92 Million
    Current Liabilities$13.13 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AVXL from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.